# KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

> **NCT06752473** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Kousai Bio Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)
- EBV

## Interventions

- **BIOLOGICAL:** KSD-101

## Key facts

- **NCT ID:** NCT06752473
- **Lead sponsor:** Kousai Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752473, "KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT06752473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*